Autonomix Investment Opportunity
$5.00
$750
Common stock
Up to $20M
Pre-money valuation is approximately $70M
The company has applied to list on NASDAQ and has reserved the symbol “AMIX” and if approved will trade immediately following the closing of the offering on NASDAQ.*
Autonomix is developing potentially revolutionary, class-leading technology that could solve some of the biggest problems in medicine, including diagnosing and treating nearly anything related to the nervous system. In total, we believe this could be a $100B market opportunity.
Our nerve-sensing technology places Autonomix at the core of an estimated $100B market opportunity. We intend to introduce our sensing and ablation technologies into this space, selling catheters to treat various conditions to the hospitals and clinics that provide treatments to patients. We anticipate that our procedures will be covered by insurance for patients.
Based on animal studies we have completed, our device is thousands of times more sensitive than what current companies doing similar work are doing. They are targeting a space with limited or inferior options for physicians to provide their patients today.
The proceeds will be used to further develop our product and perform clinical and preclinical testing to support our regulatory filings that will be necessary to clear our product for commercial use. Additionally, the proceeds will be used for working capital.
Investing in startups is risky and there is no guarantee you will get a return on your investment. However, an exit opens up the opportunity where you could convert your shares into cash or a more liquid asset. Exits include going public or getting acquired by a larger company. If the value of our company grows, then you have a higher potential of making a profit on your investment during one of these exits. No public market currently exists for the securities, and if a public market develops following the offering, it may not continue.
The funds raised in this round are expected to provide one year of cash runway for the company.
The plan is to build a successful, valuable company. Exit opportunities like an acquisition could follow in due course if we are able to demonstrate the value our technology brings to the marketplace through clinical results.
We are initially focused on treating pancreatic cancer pain as it is an area with significant unmet needs for patients.
Your shares will be held at the transfer agent on closing in your name.
Transfer agents maintain a record of ownership, including contact information, of an issuer’s registered stockholders. After the Common Stock is listed on NASDAQ, you will be able to deposit any shares you purchased with a broker. Until you deposit your shares in a brokerage account, the transfer agent will maintain the record of your ownership. Once you deposit your shares with a broker, the broker will maintain that record.
Your shares will be freely tradeable through the broker of your choice once the company is listed on NASDAQ. The transfer agent is Equity Stock Transfer “EST” – all investors will receive a Welcome Letter directly from EST with information on how to access and manage their accounts.
No, costs are the same, regardless of how you invest.
The company is a Delaware corporation.
All of Autonomix’s regulatory filings, including financial reports, can be found here: https://www.sec.gov/edgar/browse/?CIK=1617867